Taro Pharmaceutical to Invest $247 Million in Canadian R&D and Manufacturing Facility
Taro Pharmaceuticals Inc., the Canadian subsidiary of Taro Pharmaceutical Industries, based in Haifa Bay, Israel, is investing $247 million in new manufacturing and R&D equipment to expand research and production at its facility in Brampton, Ontario, Canada. The province of Ontario is contributing $7 million toward the $247-million project, which will increase Taro’s plant capacity by 50%.
Taro develops, manufactures and markets prescription and over-the-counter pharmaceutical products primarily in the United States, Canada, and Israel. Taro's primary areas of focus include pediatric creams and ointments, liquids, capsules, and tablets, mainly for the dermatological, topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic areas.